Genscript Biotech's ProBio receives $67.5m payment from LaNova Medicines

Genscript Biotech Corporation announced that its subsidiary, ProBio, has received new payments totaling approximately 479.7 million yuan ($67.5 million) under its R&A Agreement with LaNova Medicines Ltd. These payments represent the second installment of sublicense revenue related to anti-PD-1 single domain antibodies, which are integrated into LaNova's investigational PD-1/VEGF bispecific antibody, LM-299.

As of October 14, 2025, ProBio’s cumulative receipts under the R&A Agreement have reached approximately 2.0 billion yuan ($283.6 million). The anti-PD-1 single domain antibodies, licensed exclusively worldwide to LaNova, demonstrate strong binding and blockade capabilities, with potency comparable to Keytruda.

The company stated that these payments will bolster ProBio's cash reserves, supporting its ongoing efforts in new molecular discovery and development.